睿知中国医院研究地图
候选清单

西安

陕西省人民医院

Shaanxi Provincial People's Hospital

在本站收录的 61 种疾病中,这家医院列在其中 9 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

陕西省人民医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 食管鳞状细胞癌Oesophageal squamous cell carcinoma3 篇牵头论文
  2. 胃癌Stomach cancer27 篇牵头论文
  3. 乳腺癌Breast cancer18 篇牵头论文
  4. 视网膜母细胞瘤Retinoblastoma0 篇牵头论文
  5. 骨肉瘤Osteosarcoma2 篇牵头论文
  6. 神经母细胞瘤Neuroblastoma2 篇牵头论文
  7. 多发性骨髓瘤Multiple myeloma3 篇牵头论文
  8. 冠心病Coronary heart disease16 篇牵头论文牵头 1 项开放试验
  9. 先天性心脏病Congenital heart disease3 篇牵头论文

未列出的收录疾病:鼻咽癌、肝细胞癌、肺癌、胰腺癌、胶质瘤、肝母细胞瘤、脊索瘤、胃肠道间质瘤、尤文肉瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、淋巴瘤、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、脊柱侧弯、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 0020232024: 1120242025: 002025

西安有 5 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题分子标志物与基因
论文中的科室病理/检验科普外/肝胆胰外科
牵头的论文3
  1. Tumor-derived exosomal hyaluronidase 1 induced M2 macrophage polarization and promoted esophageal cancer progression.2024Experimental cell research
  2. Patterns and prognostic predictive value of perineural invasion in esophageal squamous cell carcinoma.2022BMC cancer免费全文
  3. The role of vascular invasion and lymphatic invasion in predicting recurrent thoracic oesophageal squamous cell carcinoma.2022World journal of surgical oncology免费全文
PubMed 以外找到的论文(未计入)6
  1. The impact of lymph node resection and survival prediction by machine learning in esophageal squamous cell carcinoma patients over 60 years old: a clinical trial based on the SEER database and Chinese population2025Research Square预印本
  2. Tumor marker index based on CYFRA21-1 and NSE is an important screening index for early-stage esophageal squamous cell carcinoma high-risk groups2023Research Square预印本
  3. 165. DIVERSITY OF PERINEURAL INVASION AND THEIR PREDICTIVE ROLE IN PROGNOSIS OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA2022Diseases of the Esophagus论文
  4. 167. LYMPHATIC INVASION CAN PREDICT POSTOPERATIVE LYMPH NODE RECURRENCE IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA2022Diseases of the Esophagus论文
  5. Additional file 6 of Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF12022Figshare数据集
  6. Long non-coding RNA BCAR4 aggravated proliferation and migration in esophageal squamous cell carcinoma by negatively regulating p53/p21 signaling pathway2021Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 27 篇,占 0.3%。

牵头论文
27
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 101020222023: 4420232024: 7720242025: 442025

西安有 5 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    发布
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 64 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  2. 正在招募
    Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
    分期
    不分期
    开始
    2024-09
    发布
    登记号
    NCT06128252

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学唐都医院;另有 11 家列出的医院为研究中心上海、乌鲁木齐、南京、武汉、沈阳、西安、重庆

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期手术影像与人工智能
论文中的科室普外/肝胆胰外科肿瘤内科消化/肝病科病理/检验科
牵头的论文27
  1. CT Radiomics for Predicting Outcomes in HER2-Positive Surgically Resectable Advanced Gastric Cancer: A Preliminary Study.2025Academic radiology
  2. Oleandrin Promotes Apoptosis in an Autophagy-Dependent Manner in Gastric Cancer.2025Frontiers in bioscience (Landmark edition)
  3. RBM8A promotes gastric cancer progression by binding with UPF3B to induce BBC3 mRNA degradation.2025International journal of molecular medicine免费全文
  4. INHBA, transcriptionally activated by SPI1, facilitates gastric cancer progression by inducing macrophage recruitment and M2 polarization via activating the TGF-β signaling to increase CCL2.2025Pathology, research and practice
  5. The value of the radiological diameter-to-thickness ratio in patients with HER2-positive resectable advanced gastric cancer: implications for long survival and stage migration.2024Abdominal radiology (New York)
  6. Risk factor analysis and establishment of a predictive model for complications of elderly advanced gastric cancer with Clavien-Dindo classification ≥ II grade.2024BMC cancer免费全文
  7. Gastric cancer cell-derived exosomal miR-541-5p induces M2 macrophage polarization through DUSP3/JAK2/STAT3 pathway.2024BMC cancer免费全文
  8. Rhaponticin suppresses the stemness phenotype of gastric cancer stem-like cells CD133+/CD166 + by inhibiting programmed death-ligand 1.2024BMC gastroenterology免费全文
  9. Comparison of proximal gastrectomy with tubular esophagogastric anastomosis and total gastrectomy with Roux-en-Y reconstruction in the treatment of adenocarcinoma of the esophagogastric junction of Siewert type II/III at stage II.2024BMC surgery免费全文
  10. Helicobacter pylori induce circ_0046854 to regulate microRNA-511-3p/CSF1 axis and enhance the resistance of gastric cancer to cisplatin.2024Journal of biochemical and molecular toxicology
  11. Polyhedral magnetic nanoparticles induce apoptosis in gastric cancer stem cells and suppressing tumor growth through magnetic force generation.2024Journal of controlled release : official journal of the Controlled Release Society
  12. Development and external validation of a non-invasive imaging biomarker to estimate the microsatellite instability status of gastric cancer and its prognostic value: The combination of clinical and quantitative CT-imaging features.2023European journal of radiology
  13. Immune checkpoint inhibitors are effective in the treatment of Epstein-Barr virus-associated gastric cancer: A case report.2023Medicine免费全文
  14. Safety and efficacy of indocyanine green near-infrared fluorescent imaging-guided lymph node dissection during robotic gastrectomy for gastric cancer: a systematic review and meta-analysis.2023Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  15. Evaluation of Fourier transform infrared (FTIR) spectroscopy with multivariate analysis as a novel diagnostic tool for lymph node metastasis in gastric cancer.2023Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  16. Does the LHPP gene share a common biological function in pancancer progression?2022BMC medical genomics免费全文
  17. LncRNA LINC02253 activates KRT18/MAPK/ERK pathway by mediating N6-methyladenosine modification of KRT18 mRNA in gastric cancer.2022Carcinogenesis
  18. Identification of Five N6-Methylandenosine-Related ncRNA Signatures to Predict the Overall Survival of Patients with Gastric Cancer.2022Disease markers免费全文
  19. GBAP1 polymorphisms (rs140081212, rs1057941 and rs2990220) contribute to reduced risk of gastric cancer.2022Future oncology (London, England)
  20. Safety and effectiveness of overlap esophagojejunostomy in totally laparoscopic total gastrectomy for gastric cancer: A systematic review and meta-analysis.2022International journal of surgery (London, England)
  21. Novel classification and risk model based on ferroptosis-related lncRNAs to predict oncologic outcomes for gastric cancer patients.2022Journal of biochemical and molecular toxicology
  22. Significant role of savolitinib in a case of advanced gastric cancer with abnormal mesenchymal-epithelial transition factor (MET): A case report.2022Medicine免费全文
  23. KAT7 promoted gastric cancer progression through promoting YAP1 activation.2022Pathology, research and practice
  24. Clinical significance of controlling nutritional status score (CONUT) in evaluating outcome of postoperative patients with gastric cancer.2022Scientific reports免费全文
  25. Machine learning-based gray-level co-occurrence matrix signature for predicting lymph node metastasis in undifferentiated-type early gastric cancer.2022World journal of gastroenterology免费全文
  26. JHDM1D-AS1 aggravates the development of gastric cancer through miR-450a-2-3p-PRAF2 axis.2021Life sciences
  27. Naringin induces apoptosis of gastric carcinoma cells via blocking the PI3K/AKT pathway and activating pro‑death autophagy.2021Molecular medicine reports免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  2. Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer正在招募NCT06128252研究中心不分期2024-09 启动
  3. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

乳腺癌

Breast cancer

2021–2025 年中国大陆作者发表的 16,974 篇乳腺癌 PubMed 英文论文中,这家医院牵头了 18 篇,占 0.1%。

牵头论文
18
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 6620222023: 0020232024: 5520242025: 332025

西安有 8 家医院列在乳腺癌下全国有 219 家医院列在乳腺癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    分期
    III期
    开始
    2025-04
    发布
    登记号
    NCT06790693

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心乌鲁木齐、北京、南宁、哈尔滨、天津、广州、成都、昆明、杭州、济南、襄阳、西安、长沙

  2. 正在招募
    A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
    分期
    II/III期
    开始
    2025-06
    发布
    登记号
    NCT06891833

    年龄 18 岁 至 75 岁;仅女性(登记的条件)

    牵头方不是列出的医院;另有 26 家列出的医院为研究中心上海、南宁、南昌、合肥、哈尔滨、天津、太原、安阳、广州、成都、杭州、洛阳、济南、海口、深圳、石家庄、福州、蚌埠、西安、郑州、重庆、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科放疗科

这些论文过半是实验室或动物研究。

牵头的论文18
  1. Investigating the causality and pathogenesis of multiple sclerosis in breast cancer via bioinformatics analysis.2026Multiple sclerosis and related disorders
  2. Correlation analysis of DLG5 and PD-L1 expression in triple-negative breast cancer.2025BMC cancer免费全文
  3. An injectable hydrogel for hemostasis and tumor suppression in intraoperative breast cancer.2025Biomaterials advances
  4. Computational Analysis of Exosome-Derived Signature in TNBC: Integrating Single-Cell and Bulk Transcriptomics for Prognosis Prediction.2025Clinical and translational science免费全文
  5. Identifying the mechanism of polysaccharopeptide against breast cancer based on network pharmacology and experimental verification.2024BMC cancer免费全文
  6. Development and Validation of a Nomogram for Prognosis Prediction in Patients with Synchronous Primary Thyroid and Breast Cancer Based on SEER Database.2024Cancer investigation
  7. Interactions between the tumor microbiota and breast cancer.2024Frontiers in cellular and infection microbiology免费全文
  8. Who can benefit from postmastectomy radiotherapy among HR+/HER2- T1-2 N1M0 breast cancer patients? An explainable machine learning mortality prediction based approach.2024Frontiers in endocrinology免费全文
  9. Comprehensive Molecular Analyses of an M2-Like Tumor-Associated Macrophage for Predicting the Prognosis and Immunotherapy in Breast Cancer.2024Journal of immunotherapy (Hagerstown, Md. : 1997)
  10. Perceived needs and health-related quality of life in women with breast cancer undergoing chemotherapy: a cross-sectional study.2022BMJ open免费全文
  11. Advanced glycation end products correlate with breast cancer metastasis by activating RAGE/TLR4 signaling.2022BMJ open diabetes research & care免费全文
  12. Construction of a Prognostic Nomogram Model for Patients with Mucinous Breast Cancer.2022Journal of healthcare engineering免费全文
  13. REC8 inhibits proliferation, migration and invasion of breast cancer cells by targeting CDC20.2022Molecular medicine reports免费全文
  14. Necroptosis-related lncRNA signatures determine prognosis in breast cancer patients.2022Scientific reports免费全文
  15. The inhibition of centromere protein K causes anticancer effects in breast carcinoma via effects on the FAK/PI3K/AKT/mTOR pathway.2022Toxicology and applied pharmacology
  16. CASC15 Polymorphisms are Correlated With Breast Cancer Susceptibility in Chinese Han Women.2021Clinical breast cancer
  17. Capecitabine metronomic chemotherapy combined with autologous CIK cell immunotherapy in the treatment of recurrent and metastatic triple-negative breast cancer.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  18. Effects of miR‑93 on epithelial‑to‑mesenchymal transition and vasculogenic mimicry in triple‑negative breast cancer cells.2021Molecular medicine reports免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer正在招募NCT06891833研究中心II/III期2025-06 启动
  2. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer正在招募NCT06790693研究中心III期2025-04 启动
  3. A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer进行中,不再招募NCT05346224研究中心III期2022-04 启动
  4. A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer进行中,不再招募NCT05132582研究中心III期2022-03 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年没有牵头视网膜母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

西安有 9 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.09%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

西安有 11 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

西安有 12 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.2%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 0020232024: 0020242025: 002025

西安有 4 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的多发性骨髓瘤开放试验。

这些数字背后的记录
研究主题双抗与抗体药物
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

冠心病

Coronary heart disease

2021–2025 年中国大陆作者发表的 5,119 篇冠心病 PubMed 英文论文中,这家医院牵头了 16 篇,占 0.3%。

牵头论文
16
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 1120222023: 3320232024: 2220242025: 552025

西安有 5 家医院列在冠心病下全国有 231 家医院列在冠心病下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 邀请入组
    Coronary Arterial Microcirculation and Metabolism
    分期
    未注明
    开始
    2025-02
    发布
    登记号
    NCT07074847

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:陕西省人民医院西安

  2. 正在招募
    A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
    分期
    II期
    开始
    2026-07
    发布
    登记号
    NCT07521007

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、兰州、北京、合肥、哈尔滨、天津、广州、成都、杭州、武汉、福州、苏州、西安、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科神经内科
牵头的论文16
  1. Prospective, multicenter, randomized controlled study on the efficacy and safety of intravascular ultrasound-guided drug-coated balloon for de novo small-vessel coronary lesions: Design and rationale of the DCB-IVUS trial.2026American heart journal
  2. Nε-carboxyethyl-lysin influences atherosclerotic plaque stability through ZKSCAN3 acetylation-regulated macrophage autophagy via the RAGE/LKB1/AMPK1/SIRT1 pathway.2025Cardiovascular diabetology免费全文
  3. Matrine alleviates coronary microvascular dysfunction in ischemia with non-obstructive coronary artery disease mice induced by advanced glycation end products inhibition of the reactive oxygen species-mediated endoplasmic reticulum stress i2025Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan免费全文
  4. Risk Factors for Comorbid Anxiety in Patients with Coronary Heart Disease and Association with Noise Exposure.2025Noise & health免费全文
  5. Genetic insights into circulating osteocalcin for cardiovascular diseases and the role of vascular calcification.2025Nutrition, metabolism, and cardiovascular diseases : NMCD
  6. Adenosine stress myocardial perfusion imaging and myocardial work in evaluating INOCA.2025Scientific reports免费全文
  7. The effect of vitamin D status on the occurrence of Kawasaki Disease: a meta-analysis.2024BMC pediatrics免费全文
  8. Diagnostic performance of the quantitative flow ratio and CT-FFR for coronary lesion-specific ischemia.2024Scientific reports免费全文
  9. Gelanxinning capsule improves coronary microvascular dysfunction by inhibiting inflammation and restoring endothelial function.2023European review for medical and pharmacological sciencesRCT
  10. Circulating levels of cytokines and risk of cardiovascular disease: a Mendelian randomization study.2023Frontiers in immunology免费全文
  11. Very early onset of coronary artery aneurysm in a 3-month infant with Kawasaki disease: a case report and literature review.2023Italian journal of pediatrics免费全文
  12. Integrated analysis of miRNA-mRNA regulatory network and functional verification of miR-338-3p in coronary heart disease.2022Functional & integrative genomics
  13. The usefulness of subtraction coronary computed tomography angiography for in-stent restenosis assessment of patients with CoCr stent using 320-row area detector CT.2021Medicine免费全文
  14. AGEs exacerbates coronary microvascular dysfunction in NoCAD by activating endoplasmic reticulum stress-mediated PERK signaling pathway.2021Metabolism: clinical and experimental
  15. Analysis of the association and predictive value of hyperhomocysteinaemia for obstructive coronary artery disease.2021The Journal of international medical research免费全文
  16. Relationship between serum cystatin-c and coronary lesion severity in coronary artery disease patients with a normal glomerular filtration rate.2021The Journal of international medical research免费全文
中文论文(未计入)3
  1. [Clinical experience in the treatment of incomplete Kawasaki disease with no response to intravenous immunoglobulin: a case report].2022Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics免费全文
  2. [A case of right auricle and right coronary artery perforation caused by active pacing electrodes].2022Zhonghua xin xue guan bing za zhi
  3. [Interpretation of the JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease].2021Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. Coronary Arterial Microcirculation and Metabolism邀请入组NCT07074847牵头方2025-02 启动
  2. Plaque Stability and Metabolomics in Coronary Heart Disease状态不明NCT05270330牵头方2021-07 启动
  3. Clinical Observation of Coronary Arterial Microcirculation Dysfunction in Diabetic Patients With Non- Obstructive Coronary Artery Disease状态不明NCT02748980牵头方2016-03 启动
  4. Frank Score and Coronary Artery Disease已完成NCT03177486牵头方2015-12 启动
  5. A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis正在招募NCT07521007研究中心II期2026-07 启动
  6. Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)已完成NCT04624854研究中心IV期2020-10 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性心脏病

Congenital heart disease

2021–2025 年中国大陆作者发表的 2,604 篇先天性心脏病 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025

西安有 6 家医院列在先天性心脏病下全国有 207 家医院列在先天性心脏病下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的先天性心脏病开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

陕西省人民医院

Shaanxi Provincial People's Hospital

西安

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Third Affiliated Hospital (Shaanxi Provincial People's Hospital); Affiliated Shaanxi Provincial People's Hospital; Shaanxi Provincial Peoples Hospital; Shaanxi Provincial People'S Hospital; Third Affiliated Hospital of Xi'an Jiaotong University

提出更正下载数据